Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Biomea Fusion (NASDAQ:BMEA) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $12.00 price target on the stock.

Several other equities research analysts also recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Biomea Fusion in a report on Wednesday, January 21st. Rodman & Renshaw began coverage on Biomea Fusion in a research note on Tuesday, January 13th. They issued a “buy” rating and a $8.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.63.

Biomea Fusion Stock Up 8.0%

NASDAQ:BMEA opened at $1.22 on Wednesday. Biomea Fusion has a 52 week low of $0.87 and a 52 week high of $3.08. The company has a fifty day simple moving average of $1.29 and a two-hundred day simple moving average of $1.43. The company has a market cap of $86.25 million, a price-to-earnings ratio of -0.93 and a beta of -0.20.

Biomea Fusion (NASDAQ:BMEA) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.39). On average, analysts expect that Biomea Fusion will post -3.93 EPS for the current year.

Hedge Funds Weigh In On Biomea Fusion

Hedge funds have recently modified their holdings of the business. Griffin Asset Management Inc. increased its holdings in shares of Biomea Fusion by 19.5% in the 3rd quarter. Griffin Asset Management Inc. now owns 61,300 shares of the company’s stock valued at $124,000 after acquiring an additional 10,000 shares during the period. Scientech Research LLC acquired a new stake in Biomea Fusion during the 3rd quarter worth $25,000. Engineers Gate Manager LP purchased a new position in Biomea Fusion during the 2nd quarter worth $26,000. Millennium Management LLC grew its position in Biomea Fusion by 156.7% during the 4th quarter. Millennium Management LLC now owns 25,677 shares of the company’s stock worth $32,000 after purchasing an additional 15,675 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Biomea Fusion in the third quarter valued at $32,000. 96.72% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Biomea Fusion

Here are the key news stories impacting Biomea Fusion this week:

• Positive Sentiment: High analyst optimism: multiple writeups note that ~88% of covering analysts are bullish and the consensus price target (~$6.00) implies substantial upside vs. the current share price. Analysts Sentiment on Biomea Fusion (BMEA) Remains Strong Amid Strong Diabetes Trial Results
• Positive Sentiment: Analyst upgrades and high price targets: D. Boral Capital reaffirmed a “buy” and set a $12.00 target, signaling strong upside expectations from at least one firm. Benzinga report
• Neutral Sentiment: Company update and FY‑2025 results: Biomea released its full‑year 2025 financial results and corporate highlights; the release provides operational context for investors about program progress in diabetes and obesity but does not resolve near‑term cash/earnings drag. Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
• Negative Sentiment: Quarterly EPS miss: Biomea reported ($0.64) EPS vs. consensus ($0.25), a meaningful shortfall that underscores near‑term negative earnings momentum and could pressure shares if follow‑on guidance is weak. Quarterly earnings press release
• Neutral Sentiment: Short‑interest reporting appears anomalous: multiple feeds show zero short interest/0.0 days‑to‑cover (likely a data/reporting error), so short‑squeeze risk is unclear and should not be treated as a confirmed driver without corroboration. (No reliable link available.)

About Biomea Fusion

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.